S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$229.40
-1.78 (-0.77%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$228.88
$237.80
50-Day Range
$229.40
$282.86
52-Week Range
$181.00
$324.81
Volume
293,465 shs
Average Volume
533,244 shs
Market Capitalization
$15.92 billion
P/E Ratio
458.80
Dividend Yield
N/A
Price Target
$292.33

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
27.4% Upside
$292.33 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.55mentions of Insulet in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4.11 M Sold Last Quarter
Proj. Earnings Growth
92.11%
From $0.76 to $1.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

44th out of 1,093 stocks

Surgical & Medical Instruments Industry

7th out of 106 stocks

PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
8/04/2022
Today
9/30/2022
Next Earnings (Confirmed)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$292.33
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+27.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
3.55%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.05 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
68,779,000
Market Cap
$15.92 billion
Optionable
Optionable
Beta
0.73

Social Links


Key Executives

  • Dr. James R. Hollingshead Ph.D. (Age 59)
    Pres, CEO & Director
    Comp: $69.81k
  • Mr. Wayde D. McMillan (Age 52)
    Exec. VP,CFO & Treasurer
    Comp: $946.57k
  • Mr. Charles  AlpucheMr. Charles Alpuche (Age 62)
    Exec. VP & COO
    Comp: $1.03M
  • Mr. John Wodick Kapples (Age 62)
    Sr. VP & Gen. Counsel
    Comp: $783.36k
  • Ms. Shacey  PetrovicMs. Shacey Petrovic (Age 48)
    Director & Advisor
    Comp: $1.72M
  • Mr. Bret  ChristensenMr. Bret Christensen (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $883.8k
  • Ms. Lauren Budden
    VP, Chief Accounting Officer & Controller
  • Ms. Deborah R. Gordon CPA
    VP of Investor Relations
  • Mr. Michael Spears (Age 57)
    Sr. VP of Regulatory Affairs & Compliance
  • Angela Geryak Wiczek
    Sr. Director of Corp. Communications













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2022?

12 analysts have issued 1-year price objectives for Insulet's stock. Their PODD share price forecasts range from $235.00 to $350.00. On average, they expect the company's share price to reach $292.33 in the next year. This suggests a possible upside of 27.4% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2022?

Insulet's stock was trading at $266.07 at the start of the year. Since then, PODD stock has decreased by 13.8% and is now trading at $229.40.
View the best growth stocks for 2022 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PODD earnings forecast
.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, November 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, August, 4th. The medical instruments supplier reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.21 by $0.27. The medical instruments supplier earned $299.40 million during the quarter, compared to analyst estimates of $290.87 million. Insulet had a net margin of 2.94% and a trailing twelve-month return on equity of 13.83%. The business's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its third quarter 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $322.45 million-$330.72 million, compared to the consensus revenue estimate of $309.85 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $229.40.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $15.92 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.50 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,300 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.